{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T19:49:20Z","timestamp":1777492160187,"version":"3.51.4"},"reference-count":45,"publisher":"Bentham Science Publishers Ltd.","issue":"4","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CRR"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n<jats:title>Introduction:<\/jats:title>\n<jats:p>Upadacitinib, a selective JAK1 inhibitor, has demonstrated promising results\nin the treatment of axial Spondyloarthritis (AxSpA). AxSpA management remains challenging\nsince there is a gap in knowledge regarding the potential effect of upadacitinib in axSpA patients.\nExploring novel therapeutic options is crucial. Therefore, we performed this systematic review\nand meta-analysis to summarize and synthesize results collected from available randomized--\ncontrolled trials (RCTs) about the efficacy and safety of upadacitinib for patients with axSpA.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>A systematic literature search of Medline via PubMed, Web of Science, Scopus, EBSCO,\nand Cochrane Central was conducted in October 2023. Relevant RCTs were selected, and\ntheir data were extracted and analyzed using the RevMan 5.4 software. The main outcomes were\nassessment in Spondylarthritis International Society (ASAS) 20, ASAS40, SPARCC MRI sacroiliac\njoint, and Bath Ankylosing Spondylitis disease activity index (BASDAI) 50.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Three RCTs with a total of 920 participants were included in this study. Upadacitinib\nshowed significant improvement in the ASAS40 response, ASAS20 response, BASDAI50 response,\nand SPARCC MRI Sacroiliac Joint change from baseline compared to placebo at 14-week\nduration (RR 2.19, 95% CI (1.79 to 2.68), P &lt; 0.00001), (RR 1.62, 95% CI [1.42 to 1.84), P &lt;\n0.00001), (RR 2.16, 95% CI (1.75 to 2.67), P &lt; 0.00001), and (MD -3.32 points, 95% CI (-3.96 to\n-2.68), P &lt; 0.00001) respectively. However, this efficacy decreased after the 52-week duration in\nterms of ASAS40 RR 2.19 vs. 1.02, ASAS20 RR 1.62 vs. 0.98, BASDAI 50 RR 2.16 vs. 1.05, and\nASAS Partial Remission RR 3.82 vs. 1.07.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Upadacitinib 15 mg showed satisfactory and promising efficacy in the treatment of\nAxSpA, with no difference in safety profile compared to the placebo.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0115733971296457240805064237","type":"journal-article","created":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T07:30:56Z","timestamp":1724139056000},"page":"455-467","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and Safety of Upadacitinib for Axial Spondyloarthritis: A Systematic Review and Meta-Analysis"],"prefix":"10.2174","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-2706-5275","authenticated-orcid":true,"given":"Ahmed Hamdy G.","family":"Ali","sequence":"first","affiliation":[{"name":"Department of Outpatient Therapy, Faculty of Medicine, Ogarev Mordovia State University, Saransk, Mordovia, Russia"},{"name":"Medical Research Group of Egypt, Negida Academy, Arlington, Massachusetts, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9717-4688","authenticated-orcid":true,"given":"Asmaa","family":"Elganady","sequence":"additional","affiliation":[{"name":"Medical Research Group of Egypt, Negida Academy, Arlington, Massachusetts, MA, USA"},{"name":"Faculty of Medicine,\nAlexandria University, Alexandria, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3085-6665","authenticated-orcid":true,"given":"Mahmoud Diaa","family":"Hindawi","sequence":"additional","affiliation":[{"name":"Medical Research Group of Egypt, Negida Academy, Arlington, Massachusetts, MA, USA"},{"name":"Faculty of Medicine, Al-Azhar University, Cairo, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5019-2114","authenticated-orcid":true,"given":"Ahella Ismail A.","family":"Mousa","sequence":"additional","affiliation":[{"name":"Medical Research Group of Egypt, Negida Academy, Arlington, Massachusetts, MA, USA"},{"name":"Faculty of Pharmacy, Badr University in Cairo (BUC), Badr, Cairo, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6270-3180","authenticated-orcid":true,"given":"Hatem Abdelmoneim","family":"Eldeeb","sequence":"additional","affiliation":[{"name":"Medical Research Group of Egypt, Negida Academy, Arlington, Massachusetts, MA, USA"},{"name":"Faculty of Medicine, Al-Azhar University, Cairo, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed Ramadan","family":"Fatiem","sequence":"additional","affiliation":[{"name":"Medical Research Group of Egypt, Negida Academy, Arlington, Massachusetts, MA, USA"},{"name":"Faculty of Medicine,\nAlexandria University, Alexandria, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7598-5690","authenticated-orcid":true,"given":"Yulia","family":"Skopina","sequence":"additional","affiliation":[{"name":"Department of Outpatient Therapy, Faculty of Medicine, Ogarev Mordovia State University, Saransk, Mordovia, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","volume":"390","author":"Sieper J.","year":"2017","unstructured":"Sieper J.; Poddubnyy D.; Axial spondyloarthritis. Lancet  2017,390(10089),73-84","journal-title":"Lancet"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"e001108","DOI":"10.1136\/rmdopen-2019-001108","volume":"5","author":"L\u00f3pez-Medina C.","year":"2019","unstructured":"L\u00f3pez-Medina C.; Ramiro S.; van der Heijde D.; Sieper J.; Dougados M.; Molto A.; Characteristics and burden of disease in patients with radiographic and non-radiographic axial Spondyloarthritis: a comparison by systematic literature review and meta-analysis. RMD Open  2019,5(2),e001108","journal-title":"RMD Open"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1093\/rheumatology\/kez171","volume":"58","author":"Zhao S.S.","year":"2019","unstructured":"Zhao S.S.; Ermann J.; Xu C.; Lyu H.; Tedeschi S.K.; Liao K.P.; Yoshida K.; Moots R.J.; Goodson N.J.; Solomon D.H.; Comparison of comorbidities and treatment between ankylosing spondylitis and non-radiographic axial spondyloarthritis in the United States. Rheumatology (Oxford)  2019,58(11),2025-2030","journal-title":"Rheumatology (Oxford)"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/annrheumdis-2013-204231","volume":"73","author":"Landew\u00e9 R.","year":"2014","unstructured":"Landew\u00e9 R.; Braun J.; Deodhar A.; Dougados M.; Maksymowych W.P.; Mease P.J.; Reveille J.D.; Rudwaleit M.; van der Heijde D.; Stach C.; Hoepken B.; Fichtner A.; Coteur G.; de Longueville M.; Sieper J.; Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis  2014,73(1),39-47","journal-title":"Ann Rheum Dis"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1093\/rheumatology\/kead598","volume":"63","author":"Deodhar A.","year":"2023","unstructured":"Deodhar A.; Machado PM.; M\u00f8rup M.; Taieb V.; Willems D.; Orme M.; Comparative efficacy and safety of bimekizumab in axial spondyloarthritis: A systematic literature review and network meta-analysis. Rheumatology (Oxford)  2023,63(5),1195-1205","journal-title":"Rheumatology (Oxford)"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"rkad084","DOI":"10.1093\/rap\/rkad084","volume":"7","author":"Tang H.","year":"2023","unstructured":"Tang H.; Singh B.S.M.; Fong W.; Prevalence and factors associated with fatigue in patients with axial spondyloarthritis: A systematic review and meta-analysis. Rheumatol Adv Pract  2023,7(3),rkad084","journal-title":"Rheumatol Adv Pract"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1002\/acr.21688","volume":"64","author":"Kiltz U.","year":"2012","unstructured":"Kiltz U.; Baraliakos X.; Karakostas P.; Igelmann M.; Kalthoff L.; Klink C.; Krause D.; Schmitz-Bortz E.; Fl\u00f6recke M.; Bollow M.; Braun J.; Do patients with non-radiographic axial spondylarthritis differ from patients with ankylosing spondylitis? Arthritis Care Res (Hoboken)  2012,64(9),1415-1422","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.1093\/rheumatology\/keab901","volume":"61","author":"Poddubnyy D.","year":"2022","unstructured":"Poddubnyy D.; Sieper J.; Akar S.; Mu\u00f1oz-Fern\u00e1ndez S.; Haibel H.; Hojnik M.; Ganz F.; Inman R.D.; Characteristics of patients with axial spondyloarthritis by geographic regions: PROOF multicountry observational study baseline results. Rheumatology (Oxford)  2022,61(8),3299-3308","journal-title":"Rheumatology (Oxford)"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","volume":"76","author":"van der Heijde D.","year":"2017","unstructured":"van der Heijde D.; Ramiro S.; Landew\u00e9 R.; Baraliakos X.; Van den Bosch F.; Sepriano A.; Regel A.; Ciurea A.; Dagfinrud H.; Dougados M.; van Gaalen F.; G\u00e9her P.; van der Horst-Bruinsma I.; Inman R.D.; Jongkees M.; Kiltz U.; Kvien T.K.; Machado P.M.; Marzo-Ortega H.; Molto A.; Navarro-Comp\u00e0n V.; Ozgocmen S.; Pimentel-Santos F.M.; Reveille J.; Rudwaleit M.; Sieper J.; Sampaio-Barros P.; Wiek D.; Braun J.; 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis  2017,76(6),978-991","journal-title":"Ann Rheum Dis"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1002\/art.41042","volume":"71","author":"Ward M.M.","year":"2019","unstructured":"Ward M.M.; Deodhar A.; Gensler L.S.; Dubreuil M.; Yu D.; Khan M.A.; Haroon N.; Borenstein D.; Wang R.; Biehl A.; Fang M.A.; Louie G.; Majithia V.; Ng B.; Bigham R.; Pianin M.; Shah A.A.; Sullivan N.; Turgunbaev M.; Oristaglio J.; Turner A.; Maksymowych W.P.; Caplan L.; 2019 update of the american college of rheumatology\/spondylitis association of america\/spondyloarthritis research and treatment network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol  2019,71(10),1599-1613","journal-title":"Arthritis Rheumatol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.3748\/wjg.v25.i18.2162","volume":"25","author":"Fragoulis G.E.","year":"2019","unstructured":"Fragoulis G.E.; Liava C.; Daoussis D.; Akriviadis E.; Garyfallos A.; Dimitroulas T.; Inflammatory bowel diseases and spondyloarthropathies: From pathogenesis to treatment. World J Gastroenterol  2019,25(18),2162-2176","journal-title":"World J Gastroenterol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"e001654","DOI":"10.1136\/rmdopen-2021-001654","volume":"7","author":"Sepriano A.","year":"2021","unstructured":"Sepriano A.; Ramiro S.; van der Heijde D.; Landew\u00e9 R.; Biological DMARDs and disease modification in axial spondyloarthritis: A review through the lens of causal inference. RMD Open  2021,7(2),e001654","journal-title":"RMD Open"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s40744-019-00172-9","volume":"6","author":"Mease P.J.","year":"2019","unstructured":"Mease P.J.; Liu M.; Rebello S.; Kang H.; Yi E.; Park Y.; Greenberg J.D.; Comparative disease burden in patients with rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis: Data from two corrona registries. Rheumatol Ther  2019,6(4),529-542","journal-title":"Rheumatol Ther"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"e000524","DOI":"10.1136\/rmdopen-2017-000524","volume":"3","author":"Navarro-Comp\u00e1n V.","year":"2017","unstructured":"Navarro-Comp\u00e1n V.; Plasencia-Rodr\u00edguez C.; de Miguel E.; Diaz del Campo P.; Balsa A.; Gratac\u00f3s J.; Switching biological disease- modifying antirheumatic drugs in patients with axial spondyloarthritis: results from a systematic literature review. RMD Open  2017,3(2),e000524","journal-title":"RMD Open"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"i70","DOI":"10.1136\/annrheumdis-2011-200595","volume":"71","author":"Tanaka Y.","year":"2012","unstructured":"Tanaka Y.; Maeshima Y.; Yamaoka K.; In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis. Ann Rheum Dis  2012,71(Suppl. 2),i70-i74","journal-title":"Ann Rheum Dis"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1056\/NEJMra1202117","volume":"368","author":"O\u2019Shea J.J.","year":"2013","unstructured":"O\u2019Shea J.J.; Holland S.M.; Staudt L.M.; JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med  2013,368(2),161-170","journal-title":"N Engl J Med"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","volume":"377","author":"Mease P.","year":"2017","unstructured":"Mease P.; Hall S.; FitzGerald O.; van der Heijde D.; Merola J.F.; Avila-Zapata F.; Cie\u015blak D.; Graham D.; Wang C.; Menon S.; Hendrikx T.; Kanik K.S.; Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med  2017,377(16),1537-1550","journal-title":"N Engl J Med"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1016\/S0140-6736(18)32463-2","volume":"392","author":"van der Heijde D.","year":"2018","unstructured":"van der Heijde D.; Baraliakos X.; Gensler L.S.; Maksymowych W.P.; Tseluyko V.; Nadashkevich O.; Abi-Saab W.; Tasset C.; Meuleners L.; Besuyen R.; Hendrikx T.; Mozaffarian N.; Liu K.; Greer J.M.; Deodhar A.; Landew\u00e9 R.; Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): Results from a randomised, placebo-controlled, phase 2 trial. Lancet  2018,392(10162),2378-2387","journal-title":"Lancet"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"i1","DOI":"10.1093\/rheumatology\/key280","volume":"58","author":"Tanaka Y.","year":"2019","unstructured":"Tanaka Y.; The JAK inhibitors: Do they bring a paradigm shift for the management of rheumatic diseases? Rheumatology (Oxford)  2019,58(Suppl. 1),i1-i3","journal-title":"Rheumatology (Oxford)"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1093\/rheumatology\/key339","volume":"58","author":"Choy E.H.","year":"2019","unstructured":"Choy E.H.; Clinical significance of Janus Kinase inhibitor selectivity. Rheumatology (Oxford)  2019,58(6),953-962","journal-title":"Rheumatology (Oxford)"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S0140-6736(22)01212-0","volume":"400","author":"Deodhar A.","year":"2022","unstructured":"Deodhar A.; Van den Bosch F.; Poddubnyy D.; Maksymowych W.P.; van der Heijde D.; Kim T.H.; Kishimoto M.; Blanco R.; Duan Y.; Li Y.; Pangan A.L.; Wung P.; Song I.H.; Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet  2022,400(10349),369-379","journal-title":"Lancet"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1016\/S0140-6736(19)32534-6","volume":"394","author":"van der Heijde D.","year":"2019","unstructured":"van der Heijde D.; Song I.H.; Pangan A.L.; Deodhar A.; van den Bosch F.; Maksymowych W.P.; Kim T.H.; Kishimoto M.; Everding A.; Sui Y.; Wang X.; Chu A.D.; Sieper J.; Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial. Lancet  2019,394(10214),2108-2117","journal-title":"Lancet"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/1744666X.2023.2282696","volume":"20","author":"Fukui S.","year":"2023","unstructured":"Fukui S.; Kawaai S.; Sawada H.; Kishimoto M.; Upadacitinib for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpa). Expert Rev Clin Immunol  2023,20(2),141-153","journal-title":"Expert Rev Clin Immunol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"e002280","DOI":"10.1136\/rmdopen-2022-002280","volume":"8","author":"van der Heijde D.","year":"2022","unstructured":"van der Heijde D.; Deodhar A.; Maksymowych W.P.; Sieper J.; Van den Bosch F.; Kim T.H.; Kishimoto M.; \u00d6st\u00f6r A.J.; Combe B.; Sui Y.; Duan Y.; Wung P.K.; Song I.H.; Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension. RMD Open  2022,8(2),e002280","journal-title":"RMD Open"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/art.41911","volume":"74","author":"Deodhar A.","year":"2022","unstructured":"Deodhar A.; van der Heijde D.; Sieper J.; Van den Bosch F.; Maksymowych W.P.; Kim T.H.; Kishimoto M.; Ostor A.; Combe B.; Sui Y.; Chu A.D.; Song I.H.; Safety and efficacy of upadacitinib in patients with active ankylosing spondylitis and an inadequate response to nonsteroidal antiinflammatory drug therapy: one-year results of a double-blind, placebo-controlled study and open-label extension. Arthritis Rheumatol  2022,74(1),70-80","journal-title":"Arthritis Rheumatol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","volume":"18","author":"Tanaka Y.","year":"2022","unstructured":"Tanaka Y.; Luo Y.; O\u2019Shea J.J.; Nakayamada S.; Janus kinase-targeting therapies in rheumatology: A mechanisms-based approach. Nat Rev Rheumatol  2022,18(3),133-145","journal-title":"Nat Rev Rheumatol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/BOR.0000000000000806","volume":"33","author":"Kumthekar A.","year":"2021","unstructured":"Kumthekar A.; Bittar M.; Dubreuil M.; Educational needs and challenges in axial spondyloarthritis. Curr Opin Rheumatol  2021,33(4),313-318","journal-title":"Curr Opin Rheumatol"},{"key":"ref=28","first-page":"n71","volume":"372","author":"Hoffmann B.","year":"2021","unstructured":"Hoffmann B.; Mulrow CD.; The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ  2021,372,n71","journal-title":"BMJ"},{"key":"ref=29","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions.  Available from:  https:\/\/training.cochrane.org\/handbook(accessed on 15-7-2024)"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"Ouzzani M.","year":"2016","unstructured":"Ouzzani M.; Hammady H.; Fedorowicz Z.; Elmagarmid A.; Rayyan\u2014a web and mobile app for systematic reviews. Syst Rev  2016,5(1),210","journal-title":"Syst Rev"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"Sterne J.A.C.","year":"2019","unstructured":"Sterne J.A.C.; Savovi\u0107 J.; Page M.J.; Elbers R.G.; Blencowe N.S.; Boutron I.; Cates C.J.; Cheng H.Y.; Corbett M.S.; Eldridge S.M.; Emberson J.R.; Hern\u00e1n M.A.; Hopewell S.; Hr\u00f3bjartsson A.; Junqueira D.R.; J\u00fcni P.; Kirkham J.J.; Lasserson T.; Li T.; McAleenan A.; Reeves B.C.; Shepperd S.; Shrier I.; Stewart L.A.; Tilling K.; White I.R.; Whiting P.F.; Higgins J.P.T.; RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ  2019,366,l4898","journal-title":"BMJ"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"ii1","DOI":"10.1136\/ard.2008.104018","volume":"68","author":"Sieper J.","year":"2009","unstructured":"Sieper J.; Rudwaleit M.; Baraliakos X.; Brandt J.; Braun J.; Burgos-Vargas R.; Dougados M.; Hermann K-G.; Landew\u00e9 R.; Maksymowych W.; van der Heijde D.; The Assessment of SpondyloArthritis international Society (ASAS) handbook: A guide to assess spondyloarthritis. Ann Rheum Dis  2009,68(Suppl. 2),ii1-ii44","journal-title":"Ann Rheum Dis"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s11926-015-0522-3","volume":"17","author":"Landew\u00e9 R.","year":"2015","unstructured":"Landew\u00e9 R.; van Tubergen A.; Clinical tools to assess and monitor spondyloarthritis. Curr Rheumatol Rep  2015,17(7),47","journal-title":"Curr Rheumatol Rep"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/art.21445","volume":"53","author":"Maksymowych W.P.","year":"2005","unstructured":"Maksymowych W.P.; Inman R.D.; Salonen D.; Dhillon S.S.; Williams M.; Stone M.; Conner-spady B.; Palsat J.; Lambert R.G.W.; Spondyloarthritis research Consortium of Canada magnetic resonance imaging index for assessment of sacroiliac joint inflammation in ankylosing spondylitis. Arthritis Care Res  2005,53(5),703-709","journal-title":"Arthritis Care Res"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1136\/ard.2003.016386","volume":"63","author":"Rudwaleit M.","year":"2004","unstructured":"Rudwaleit M.; Listing J.; Brandt J.; Braun J.; Sieper J.; Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor blockers in ankylosing spondylitis. Ann Rheum Dis  2004,63(6),665-670","journal-title":"Ann Rheum Dis"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1136\/annrheumdis-2018-213184","volume":"77","author":"Machado P.M.","year":"2018","unstructured":"Machado P.M.; Landew\u00e9 R.; van der Heijde D.; Ankylosing Spondylitis Disease Activity Score (ASDAS): 2018 update of the nomenclature for disease activity states. Ann Rheum Dis  2018,77(10),1539-1540","journal-title":"Ann Rheum Dis"},{"key":"ref=37","author":"Weisman M.H.","year":"2006","unstructured":"Weisman M.H.; van der Heijde D.; Reveille J.D.;  Ankylosing Spondylitis and the Spondyloarthropathies  2006","journal-title":"Ankylosing Spondylitis and the Spondyloarthropathies"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1136\/ard.62.1.20","volume":"62","author":"Doward L.C.","year":"2003","unstructured":"Doward L.C.; Spoorenberg A.; Cook S.A.; Whalley D.; Helliwell P.S.; Kay L.J.; McKenna S.P.; Tennant A.; van der Heijde D.; Chamberlain M.A.; Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis  2003,62(1),20-26","journal-title":"Ann Rheum Dis"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.3899\/jrheum.200708","volume":"47","author":"Kiltz U.","year":"2020","unstructured":"Kiltz U.; Wendling D.; Braun J.; ASAS health index: The \u201call in one\u201d for spondyloarthritis evaluation? J Rheumatol  2020,47(10),1457-1460","journal-title":"J Rheumatol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1136\/ard.2007.074724","volume":"67","author":"van der Heijde D.","year":"2008","unstructured":"van der Heijde D.; Landew\u00e9 R.; Feldtkeller E.; Proposal of a linear definition of the Bath Ankylosing Spondylitis Metrology Index (BASMI) and comparison with the 2-step and 10-step definitions. Ann Rheum Dis  2008,67(4),489-493","journal-title":"Ann Rheum Dis"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1136\/ard.62.2.127","volume":"62","author":"Heuft-Dorenbosch L.","year":"2003","unstructured":"Heuft-Dorenbosch L.; Spoorenberg A.; van Tubergen A.; Landew\u00e9 R.; van ver Tempel H.; Mielants H.; Dougados M.; van der Heijde D.; Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis  2003,62(2),127-132","journal-title":"Ann Rheum Dis"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"Egger M.","year":"1997","unstructured":"Egger M.; Smith G.D.; Schneider M.; Minder C.; Bias in meta-analysis detected by a simple, graphical test. BMJ  1997,315(7109),629-634","journal-title":"BMJ"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1136\/ard-2022-222608","volume":"81","author":"van der Heijde D.","year":"2022","unstructured":"van der Heijde D.; Baraliakos X.; Sieper J.; Deodhar A.; Inman R.D.; Kameda H.; Zeng X.; Sui Y.; Bu X.; Pangan A.L.; Wung P.; Song I.H.; Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: A double-blind, randomised, placebo-controlled phase 3 trial. Ann Rheum Dis  2022,81(11),1515-1523","journal-title":"Ann Rheum Dis"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s13075-023-03128-1","volume":"25","author":"Baraliakos X.","year":"2023","unstructured":"Baraliakos X.; van der Heijde D.; Sieper J.; Inman R.D.; Kameda H.; Li Y.; Bu X.; Shmagel A.; Wung P.; Song I.H.; Deodhar A.; Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study. Arthritis Res Ther  2023,25(1),172","journal-title":"Arthritis Res Ther"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1093\/rheumatology\/keac551","volume":"62","author":"Russell M.D.","year":"2023","unstructured":"Russell M.D.; Dey M.; Flint J.; Davie P.; Allen A.; Crossley A.; Frishman M.; Gayed M.; Hodson K.; Khamashta M.; Moore L.; Panchal S.; Piper M.; Reid C.; Saxby K.; Schreiber K.; Senvar N.; Tosounidou S.; van de Venne M.; Warburton L.; Williams D.; Yee C.S.; Gordon C.; Giles I.; Giles I.; Roddy E.; Armon K.; Astell L.; Cotton C.; Davidson A.; Fordham S.; Jones C.; Joyce C.; Kuttikat A.; McLaren Z.; Merrison K.; Mewar D.; Mootoo A.; Williams E.; British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids. Rheumatology (Oxford)  2023,62(4),e48-e88","journal-title":"Rheumatology (Oxford)"}],"container-title":["Current Rheumatology Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115733971296457240805064237","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/233206\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115733971296457240805064237","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T06:57:58Z","timestamp":1758005878000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/233206\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0115733971296457240805064237","relation":{},"ISSN":["1573-3971"],"issn-type":[{"value":"1573-3971","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-02-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-24","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}